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ABSTRACT
◥
Purpose: Patients with advanced gastric/gastroesophageal junc-
tion cancer (GC/GEJC) have limited treatment options after first-
line therapy. Bintrafusp alfa is a first-in-class bifunctional fusion
protein composed of the extracellular domain of the TGFbRII
receptor (a TGFb “trap”) fused to a human IgG1 antibody against
programmed death ligand 1 (PD-L1), potentially offering a new
treatment approach for these patients. We report results for bin-
trafusp alfa in GC/GEJC.
Patients and Methods: Asian patients with recurrent GC/GEJC
for whom standard therapy does not exist or for whom standard
therapy has failed enrolled in this expansion cohort of an ongoing
phase I trial and received bintrafusp alfa 1,200 mg once every
2 weeks until disease progression, unacceptable toxicity, or with-
drawal. The primary objective was to assess safety/tolerability.
Results: By July 23, 2018, 31 heavily pretreated patients received
bintrafusp alfa for a median of 10.1 weeks; 3 patients remained on
treatment. Six patients (19%) experienced grade 3 treatment-related
adverse events (AE); no grade 4 events occurred. One on-treatment
death occurred (sudden death); rupture of a preexisting thoracic aortic
aneurysm was the suspected cause. Ten patients (32%) had immune-
related AEs. The confirmed objective response rate per independent
review committee was 16%; disease control rate was 26%. Median
duration of response was 8.7 months (range, 2.4–12.4þ). Responses
occurred irrespective of PD-L1 expression or microsatellite instability
status and appeared to correlate with high tumor TGFB1 levels.
Conclusions: In this first evaluation in Asian patients with heavily
pretreated advanced GC/GEJC, bintrafusp alfa demonstrated a man-
ageable safety profile and clinical activity.
Introduction
Gastric cancer, including gastroesophageal junction cancer (GEJC),
is the fifth most common cancer in the world and the third leading
cause of cancer-related death worldwide (1). Approximately 60% of
gastric cancer cases occur in eastern Asia, which has the highest
estimated mortality rate for gastric cancer worldwide (1). The prog-
nosis is often poor because gastric cancer is an aggressive disease and,
except in Japan and South Korea, is mostly diagnosed in advanced
stages (2, 3). Many patients present with metastatic disease at diag-
nosis, with progression-free survival (PFS) rarely exceeding 6 months
with most first-line chemotherapy treatments (3–5).
Tumor characteristics known to have prognostic or predictive
importance in GC/GEJC include PD-L1 expression, microsatellite
instability (MSI) status, mutational load, Epstein–Barr virus (EBV)
infection, and immune phenotype (2, 5–9). In addition, many recent
anticancer treatments focus on modulating the tumor microenviron-
ment to prevent cancer progression (10). TGFb, a cytokine that can act
in the tumor microenvironment, can promote epithelial–
mesenchymal transition, increase angiogenesis, and mediate tumor
cell transition to amore stem-like and invasive cell phenotype (11, 12).
TGFb-mediated signaling can suppress immune surveillance and is
associated with larger tumor volume, disease progression, and reduced
survival for patients with gastric cancer (11–16).
Currently, there is no standard third-line therapy for GC/GEJC.
International treatment recommendations include chemotherapy
regimens, such as trifluridine/tipiracil (TAS-102) and PD-1 inhibitors,
as well as second-line treatment options that were not used in prior
therapy (2, 5). Data from large phase II and III trials show median
overall survival (OS) ranging from 5.3 to 6.7 months and objective
response rates (ORR) of 4% to 12% with these agents in unselected
patients with pretreated advanced GC/GEJC (17–20). In addition,
recent phase III studies of immune checkpoint inhibitors (ICI) com-
pared with chemotherapy failed to meet their primary endpoint of
OS, highlighting the need to investigate new treatment strategies in
GC/GEJC (20, 21).
TGFb is a potent immune suppressor and has been implicated in
decreasing responsiveness to ICIs (22). In fact, the combined use of a
TGFb blocker and an ICI has shown an elevated effect over either agent
alone (22–26). Because of this, inhibiting TGFb activity in the tumor
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microenvironment while simultaneously blocking an additional
immunosuppressive cellular mechanism, such as the PD-L1 path-
way, may provide a novel treatment approach and potentially
enhance clinical benefit compared with established anti–PD-(L)1
monotherapies (27, 28).
Bintrafusp alfa (M7824) is afirst-in-class bifunctional fusionprotein
composed of the extracellular domain of the human TGFb receptor II
(TGFbRII or TGFb “trap”) fused via a flexible linker to the C-terminus
of each heavy chain of an IgG1 antibody blocking PD-L1 (27).
Preclinical studies in murine models indicate that bintrafusp alfa can
accumulate in the tumor microenvironment and reduce intratumoral
TGFb signaling and improve antitumor activity compared with either
a TGFb “trap” or an anti–PD-L1 antibody alone (27, 29). In addition,
bintrafusp alfa showed a manageable safety profile and early signs of
clinical efficacy in a phase I study of patients with heavily pretreated
advanced solid tumors (NCT02517398; ref. 28). The objective of this
trial was to assess the safety and tolerability of bintrafusp alfa in Asian
patients with heavily pretreated advanced GC/GEJC.
Patients and Methods
Study design and patients
NCT02699515 is an ongoing, open-label, phase I trial of bintrafusp
alfa withmultiple solid tumor expansion cohorts. This report describes
an expansion cohort of Asian patients with histologically or cytolog-
ically confirmed, recurrent or refractory, unresectable stage IV
GC/GEJC for whom standard therapy does not exist or for whom
standard therapy has failed. Tumor histology was initially captured
using the Japanese or World Health Organization classification sys-
tems and later mapped to the Lauren classification system (Supple-
mentary Table S1; refs. 30–33).
Eligible patients were ages ≥20 years, had an Eastern Cooperative
Oncology Group (ECOG) performance status ≤1, and measurable
disease by RECIST version 1.1 (RECIST 1.1). Patient selection was not
based on PD-L1 expression or other biomarkers. Patients were inel-
igible for the study if they had active or previous central nervous system
metastases or received prior treatment with ICIs or any therapy
targeting TGFb/TGFb receptor. Full inclusion and exclusion criteria
can be found in Supplementary Table S2.
This study was conducted in accordance with the ethical principles
of the Declaration of Helsinki. Each patient provided written informed
consent before study enrollment. Independent ethics committees or
Institutional Review Boards at all participating institutions reviewed
the study protocol with favorable opinions/approval. The study was
conducted in accordance with international standards of good clinical
practice consistent with the International Conference on Harmonisa-
tion Topic E6 Good Clinical Practice.
Treatment and assessments
Patients received bintrafusp alfa at the recommended phase II dose
of 1,200 mg via intravenous infusion over 1 hour once every 2 weeks
until confirmed disease progression, unacceptable toxicity, or trial
withdrawal (34). Tumor responses were assessed by CT or MRI every
6weeks until disease progression during the treatment period andwere
evaluated according to RECIST 1.1. At the end of treatment, patients
without progressive disease had assessments every 12 weeks. Dosing
modifications, such as changes in infusion rate and dose delays, were
permitted; however, dose reductions were not. All responses and
disease progression were confirmed by additional scans, with an
independent review committee (IRC) performing a blinded determi-
nation as to whether the criteria for response or progression had been
met.
Adverse events (AE) were evaluated according to NCI-CTCAE
v4.03. Immune-related AEs (irAE) were identified using a pre-
specified list of MedDRA terms and must have had onset after the
first study drug administration and no more than 90 days after last
dose. In addition, irAEs must have been treated with corticoster-
oids, immunosuppressants, or hormonal therapy, and have no
clear etiology. Safety was assessed and documented throughout
the trial, including monitoring for AEs, performance status eval-
uation, physical examination, and clinical laboratory tests. Elec-
trocardiograms were performed at screening and at multiple
treatment visits until week 13. After week 13, electrocardiograms
were performed until disease progression, as well as at the end-of-
treatment visit and safety follow-up visit. All patients had a visit
scheduled for 10 weeks (2 weeks) after the last administration of
bintrafusp alfa for an assessment of safety parameters, including
treatment-related AEs, concomitant medications, and further anti-
cancer therapy.
Endpoints
The primary endpoint of this expansion cohort was safety/tolera-
bility. Secondary endpoints included confirmed best overall response
per RECIST 1.1, duration of response, disease control rate (DCR), PFS,
and OS. Key exploratory endpoints were evaluation of potential
predictive markers in tumors, including PD-L1 expression, EBV
status, neoantigen count, MSI status, gene expression, and immune
phenotype.
Statistical analysis
The goal of this expansion cohort was to explore the initial clinical
activity of bintrafusp alfa in GC/GEJC and was viewed as hypothesis-
generating. Thirty patients were planned for this expansion cohort.
The sample size was determined to obtain preliminary estimates of
efficacy. The primary data cutoff date was 6 months after the last
patient started treatment; the analysis presented here is a follow-up
analysis. The ORRwas determined as the proportion of patients with a
confirmed best overall response of complete response (CR) or partial
response (PR). The uncertainty of estimates was assessed by calcu-
lating a 95% exact (Clopper–Pearson) CI. The DCR was defined as the
Translational Relevance
Gastric and gastroesophageal junction cancers (GE/GEJC) rep-
resent a common and lethal group of cancers. Although immune
checkpoint inhibitors can offer therapeutic benefit, simultaneously
targeting multiple cancer-related pathways, such as TGFb and
PD-L1, with a single agent may enhance the antitumor activity
observed when targeting a single pathway individually. We report
results from the first phase I evaluation of a bifunctional agent
targeting both TGFb and PD-L1 in GC/GEJC. Bintrafusp alfa is a
first-in-class bifunctional fusion protein composed of the extra-
cellular domain of the TGFbRII receptor (a TGFb “trap”) fused to a
human IgG1 antibody blocking PD-L1. In this ongoing trial,
bintrafusp alfa had a manageable safety profile in Asian patients
with heavily pretreated advanced GC/GEJC that was consistent
with previous reports for this treatment in solid tumors. In
addition, an objective response rate of 16% and prolonged duration
of response [median, 8.7 months (range, 2.4–12.4þ)] were
observed with bintrafusp alfa.
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proportion of patients with a confirmed best overall response of CR,
PR, stable disease (SD), or non-CR/non-progressive disease (PD).
Duration of response, PFS, and OS were analyzed using the Kaplan–
Meier method.
Exploratory endpoints and procedures
PD-L1 protein expression was detected using IHC staining of for-
malin-fixed, paraffin-embedded tumor tissue using an anti–PD-L1
rabbit mAb clone 22C3. PD-L1 expression was scored using the
combined positive score (CPS), which represents the proportion
of tumor and tumor-associated immune cells showing membranous
PD-L1 staining. A threshold of 1 was used to classify samples as either
PD-L1 positive (≥1) or PD-L1 negative (<1).
Gene expression analysis was performed using RNA sequencing
(RNAseq) data that were generated from formalin-fixed, paraffin-
embedded archival tumor samples by Asuragen using standard pro-
tocols based on ribosomal depletion. Sequencing reads were aligned
against the Ensembl 75 human genome (GRCh37 February 2014)
using Bowtie2 version 2.2.3 (Johns Hopkins University, Baltimore,
MD; ref. 35). Gene expression was determined using RSEM version
1.2.31 with Ensembl gene annotations. Hypothesis testing was
performed by comparing RSEM-computed expected counts (36).
Transcript-per-million values were upper-quartile normalized and
log transformed for further analysis.
Tumor EBV status was determined by RNAseq. Kallisto46 version
0.43.1 was used to align RNAseq reads to a transcriptome containing
the human Ensembl transcripts (version 91, GRCh38) and viral
genomes from the National Center for Biotechnology Information
collection. The EBVcontent in each samplewas assessed as the fraction
of reads mapping to any EBV viral genome. To determine a cutoff (in
terms of fraction of viral reads), the same pipeline was applied to
publicly available samples from SRP055009 and SRP151215, which
included EBV-transformed cell lines andwere used as positive controls
for viral transformation (37–39).
Tumor neoantigen count was measured using by RNAseq by
performing a total RNA extraction, random priming library prep-
aration, and ribosomal depletion by Asuragen. Tumor samples
were sequenced at 250 to a target of 108 read pairs on an Illumina
HiSeq System (Illumina). Whole-exome sequencing was performed
by Expression Analysis from matched peripheral blood samples
using an Agilent SureSelect Human All Exon V5 Kit (Agilent
Technologies); sequencing was done on an Illumina HiSeq System
with a target of 100 coverage. RNAseq reads were mapped to
hg19 and the Ensembl gene annotations (ensGene; University of
California, Santa Cruz, CA) using RNA-STAR version 2.5.0b and
whole-exome reads were mapped to hg19 using BWA-MEM
version 0.7.12 (40, 41). Mutation calling was performed on paired
BAM files (RNAseq tumor and whole-exome normal samples)
using VarDictJava version 1.4.2, and the resulting mutations were
annotated using Ensembl Variant Effect Predictor version 85 to
determine the location and type of mutation (42, 43). HLA typing
was performed on the RNAseq data using OptiType version 1.0.1.
The HLA typing and mutation information were aggregated using
a custom Python program which then ran NetMHCPan version 3.0
to determine the mutant and wild-type IC50s of peptides, including
the mutation site. Following filtering of neoantigens with an IC50
>500 nmol/L, a neoantigen count was produced for each sample.
Furthermore, an expression-adjusted neoantigen score was pro-
duced that weighted each neoantigen according to its expression
level. Finally, the per-sample values were normalized across the
dataset by inverse of the number of reads mapped to genes in each
sample.
MSI status was determined using the IdyllaTM MSI Assay (Bio-
cartis) according to the manufacturer's specifications using patient
tumor samples (44).
Tumor samples were used to determine immune phenotype
based on available IHC data (PD-L1 stain and PD-L1 negative
control) and hematoxylin and eosin staining. An exploratory clas-
sification system was used to categorize tumors as having an
immune-inflamed (immune cells in direct physical contact with
tumor cells), immune-excluded (≥1% of tumor stroma area pop-
ulated by lymphocytes, immune cells possibly located in immediate
vicinity of tumor cells but not efficiently infiltrating tumor cell
clusters, and very infrequent physical contact between lymphocytes
and tumor cells), or immune desert (<1% of tumor stroma area
populated by lymphocytes, no dense immune cell infiltrates, and no
contact of immune cells with tumor cells) phenotype. This system
was developed from methods previously described by Mariathasan
and colleagues (22). A pathologist who was masked to the response
data scored the scanned slides and determined the corresponding
immune phenotype.
Availability of materials and data
For all new products or new indications approved in both the
European Union and the United States after January 1, 2014,
Merck KGaA, Darmstadt, Germany will share patient-level and
study-level data after deidentification, as well as redacted study
protocols and clinical study reports from clinical trials in patients.
Any requests for these data by qualified scientific and medical
researchers for legitimate research purposes will be subject
to Merck KGaA's Data Sharing Policy. All requests should be
submitted in writing to Merck KGaA's data sharing portal (https://
www.merckgroup.com/en/research/our-approach-to-research-and-
development/healthcare/clinical-trials/commitment-responsible-data-
sharing.html).WhenMerckKGaAhas a coresearch, codevelopment, or
comarketing or copromotion agreement, or when the product has been
out-licensed, the responsibility for disclosure might be dependent on
the agreement between parties. Under these circumstances, Merck
KGaA will endeavor to gain agreement to share data in response to
requests.
Results
Patient demographics and treatment
From January 11, 2017 to August 7, 2017, 44 patients were
screened and 31 were enrolled at up to 30 trial centers in Japan,
South Korea, and Taiwan. The median age was 64 years (range,
45–82) and most patients had an ECOG performance status of 1
[n ¼ 23 (74%)]. All patients had previous anticancer therapy, with
the majority receiving ≥3 prior lines of treatment for locally
advanced and/or metastatic disease [n ¼ 19 (61%)]. In addition,
74% of patients (n ¼ 23) had a PD-L1 CPS ≥1 and were charac-
terized as having PD-L1–positive tumors (Table 1). Twelve patients
(39%) had tumors with PD-L1 CPS ≥10.
As of July 23, 2018, patients received bintrafusp alfa for a median of
10.1weeks (range, 2.0–72.0) and theKaplan–Meier estimate ofmedian
follow-up was 10.1 months (range, 0.5–16.8). Three patients (10%)
remained on treatment; disease progression [n ¼ 20 (65%)] was the
most common primary reason for treatment termination (Supple-
mentary Fig. S1).
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Safety
Among 31 patients, 16 (52%) experienced a treatment-related AE
(TRAE) of any grade, most commonly rash maculopapular [n ¼ 7
(23%)], rash [n¼ 5 (16%)], pruritus [n¼ 3 (10%)], and fatigue [n¼ 3
(10%; (Table 2)]. Grade 3 TRAEs occurred in 6 patients (19%),
including anemia [n ¼ 2 (6%)], diarrhea, hepatic function abnor-
mal, rash, rash maculopapular, and fracture [n ¼ 1 (3%) each].
Two of these events (hepatic function abnormal and fracture) led
to permanent treatment discontinuation. No patient experienced a
grade 4 TRAE. On-treatment death occurred in 1 patient (3%;
sudden death) after 5 doses of bintrafusp alfa. The cause of death
was assessed by the investigator as treatment-related, confounded
by suspected rupture of a preexisting thoracic aortic aneurysm that
measured approximately 50 mm and was thought to be stable.
Further radiographic diagnostic information was not provided,
and no concomitant medication was recorded. No irAEs were
reported by this patient. An autopsy was refused by the family, and
therefore the definitive cause of death could not be determined.
One patient (3%) experienced a potentially TGFb-related skin
lesion (keratoacanthoma of maximum grade 2), which was well
managed with surgical excision and did not lead to treatment
discontinuation. Infusion-related reactions occurred in 2 patients
(6%; grades 1 and 2), which resolved and did not result in
treatment discontinuation. Ten patients (32%) had at least one
irAE; immune-related rash occurred in all patients with an irAE.
No irAEs were above grade 3.
Efficacy
As per IRC assessment, responses were confirmed in 5 of 31 patients
[16% (95%CI, 6–34)], includingoneCR.TheDCRwas26% (95%CI, 12–
45; Table 3; Fig. 1). There was good concordance between IRC- and
investigator-assessed best overall response (Supplementary Table S3).
Median duration of response was 8.7 months (range, 2.4–12.4þ), with
one PR ongoing for 12.4þ months at the time of data cutoff. An
additional patient with a PR had a duration of response of 6.9 months
that was considered ongoing as of the last assessment; however, the
patientwas later lost to follow-up anddiscontinued treatment due toAEs.
The median PFS per IRC assessment was 1.3 months (95% CI, 1.2–
2.6), with a 6-month rate of 17% (95% CI, 6–32) and 12-month rate of
11% (95%CI, 3–27).Median PFSwas 2.1months (95%CI, 1.2–3.9) per
investigator assessment (Supplementary Fig. S2). The median OS was
10.1 months (95% CI, 4.5–12.8), with 6- and 12-month rates of 63%
(95% CI, 43–77) and 41% (95% CI, 23–58), respectively (Fig. 2).
Exploratory analysis showed PD-L1 expression was not predictive
of response (Table 3; Fig. 3) and did not impact survival (Fig. 2). The
IRC-assessed ORR was similar for patients with PD-L1–positive
disease, regardless of CPS cutoff [CPS ≥1, 17% (n ¼ 4 of 23); CPS
≥10, 17% (n¼ 2 of 12)]. There was also no strong association between
response andHER2 status, EBV infection, tumor neoantigen count, or
MSI-high status (Table 3; Fig. 3). Interestingly, high expression of
TGFB1 in tumor samples enriched for response to bintrafusp alfa
(Fig. 3). In addition, responses were most common (n¼ 4) in tumors
with an inflamed immune phenotype (Supplementary Fig. S3).
Discussion
In this first evaluation of bintrafusp alfa in Asian patients with
heavily pretreated advanced GC/GEJC (61% received ≥3 prior lines of
Table 1. Baseline patient and disease characteristics.




Age, median (range), years 64 (45–82)























EBV status, n (%)
Positive 3 (10)
Negative 28 (90)
Abbreviation: NE, not evaluable.
aNeoadjuvant and adjuvant therapy were included if disease progression
occurred within 6 months of the treatment start date.
bOne patient had incomplete dates recorded for adjuvant therapy and was
considered as having only one prior line of therapy.
cHistology was initially captured using the Japanese or World Health Organi-
zation classification systems and later mapped to the Lauren classification
system (Supplementary Table S1).
Table 2. Incidence of TRAEs of any grade occurring in ≥5% of
patients or of grade ≥3.
n (%) Any grade Grade 3 Grade 4 Grade 5
Any TRAE 16 (52) 6 (19) 0 1 (3)
Rash maculopapular 7 (23) 1 (3) 0 0
Rash 5 (16) 1 (3) 0 0
Fatigue 3 (10) 0 0 0
Pruritus 3 (10) 0 0 0
Anemia 2 (6) 2 (6) 0 0
Diarrhea 2 (6) 1 (3) 0 0
Infusion-related reaction 2 (6) 0 0 0
Hepatic function abnormal 1 (3) 1 (3) 0 0
Fracturea 1 (3) 1 (3) 0 0
Sudden deathb 1 (3) 0 0 1 (3)
Skin lesionsc 1 (3) 0 0 0
aIn a 70-year-old patient due to osteoporosis and long-term use of rosuvastatin
calcium as a cosuspect drug, as conferred by the investigator.
bThe cause of death, assessed by the investigator as treatment related, was
suspected to be rupture of a preexisting thoracic aortic aneurysm.
cIncludes actinic keratosis, basal cell carcinoma, hyperkeratosis, keratoa-
canthoma, and squamous cell carcinoma of the skin NCI-CTCAE v4.03 preferred
terms. One patient (3%) had grade 2 keratoacanthoma.
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therapy for locally advanced and/or metastatic disease), treatment had
amanageable safety profile with 19% of patients experiencing a grade 3
TRAE and no grade 4 events. One treatment-related death occurred in
a patient with a history of thoracic aortic aneurysms. Rashes, including
rash maculopapular, were the most common TRAEs; however, these
events were mild and resolved with simple medical measures. Rashes
were not assessed as infusion-related reactions but were a common
irAE. Skin lesions, which are anticipated AEs with TGFb inhibition
and other kinase inhibitors which may impact TGFb signaling, were
reported in 1 patient and did not lead to treatment discontinua-
tion (45). Overall, the safety profile in this cohort was consistent with
previously reported data for bintrafusp alfa in other solid tumors (28).
In addition, the safety profile of bintrafusp alfa was comparable with
that reported in phase II and III trials of PD-1 inhibitors in similar
populations (18–20).
Treatment with bintrafusp alfa resulted in a median OS of
10.1 months and ORR of 16%. These outcomes compare favorably
with historical findings from large phase II and III studies of
internationally recommended treatments for pretreated GC/GEJC,
such as TAS-102 and PD-1 inhibitors, in the overall PD-L1–
unselected population. In these studies, including the phase III
ATTRACTION-2 study which evaluated Asian patients, median OS
ranged from 5.3 to 6.7 months and ORRs were between 4% and
12% (17–20). Although results with bintrafusp alfa are encouraging,
it is important to note that results of this single-arm, phase I study
cannot be compared directly with these historical findings due to
key differences in study design, eligibility criteria, and patient
populations. Larger studies with an active comparator are required
to determine the clinical benefit of dual inhibition of TGFb and PD-
L1 in GC/GEJC.
Unlike results for PD-1 inhibitors in GC/GEJC, there was no clear
association between efficacy of bintrafusp alfa and PD-L1 expres-
sion (19, 20, 46). While the results must be interpreted cautiously due
to the small number of patients, the IRC-assessed ORR was 17% for
PD-L1–negative patients. Future studies are needed to confirmwheth-
er bintrafusp alfa could provide therapeutic benefit for patients who do
not typically respond to PD-1 inhibitors, such as PD-L1–negative
patients. In addition, EBV-positivity and MSI status did not predict
response to bintrafusp alfa (6, 19, 20, 46).
Table 3. Efficacy outcomes.
IRC Investigator
(N ¼ 31) (N ¼ 31)
Confirmed best overall response, n (%)
CR 1 (3) 2 (6)
PR 4 (13) 5 (16)
SD 2 (6) 5 (16)
Non-CR/non-PDa 1 (3) 0
PD 21 (68) 16 (52)
NE 2 (6) 3 (10)
ORR, n (%, 95% CI) 5 (16, 6–34) 7 (23, 10–41)
DCR, n (%, 95% CI) 8 (26, 12–45) 12 (39, 22–58)
Median duration of response, mo 8.7 9.0
Range 2.4–12.4þ 2.4–12.3þ
ORR by PD-L1 expression, n (%)
Positive (n ¼ 23) 4 (17) 4 (17)
Negative (n ¼ 6) 1 (17) 2 (33)
NE (n ¼ 2) 0 1 (50)
ORR by HER2 status, n (%)
0 (n ¼ 11) 2 (18) 2 (18)
1þ (n ¼ 6) 1 (17) 1 (17)
2þ (n ¼ 1) 0 0
3þ (n ¼ 3) 1 (33) 2 (67)
NE (n ¼ 10) 1 (10) 2 (20)
ORR by MSI status, n (%)
MSI-H (n ¼ 1) 0 0
MSS (n ¼ 13) 2 (15) 3 (23)
NE (n ¼ 17) 3 (18) 4 (24)
Abbreviations: MSI-H, microsatellite instability-high; MSS, microsatellite stable;
NE, not evaluable.
aNon-CR/non-PD applies to patients with no target lesions and is defined as
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Change in target lesions by IRC assessment. Twopatients are not showndue to either nopostbaseline assessment or no target lesions identifiedprior to thefirst dose.
NE, not evaluable. aPatient was lost to follow-up after the last assessment of PR and later discontinued treatment. bPercent change in sum of diameters was not
100% because patient had only lymph node lesions.
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Results of exploratory analysis revealed responses to bintrafusp alfa
were enriched in patients with high tumor TGFB1 levels, possibly
underscoring the value of dual inhibition of both the TGFb and PD-L1
pathways as a potential therapeutic option for patients with GC/GEJC.
Larger studies will be needed to confirm this observation and to
determinewhetherTGFB1 expression correlatedwith other pathologic
features or efficacy outcomes. Furthermore, additional analyses,
including a comparison of tumor TGFB1 expression before, during,
and after treatment, are of interest.
In conclusion, bintrafusp alfa had a manageable safety profile and
showed signs of clinical activity by eliciting durable responses in
this phase I study of Asian patients with heavily pretreated advanced
GC/GEJC. Further study of bintrafusp alfa in patients with advanced
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A, IRC-assessed PFS. B, OS. NE, not estimable. aTwo patients had nonevaluable PD-L1 expression.
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A, Best change in sum of diameters per IRC assessment and neoantigen count. Two patients, including 1 with EBV–positive disease, are not shown due to either no
postbaseline assessment or no target lesions identified prior to the first dose. B–G, RNAseq analysis by IRC-assessed best overall response. One patient with a
confirmed best overall response of PDwhose tumor sample had abnormally few detectable genes in RNAseq, and 1 patient with a confirmed best overall response of
SD forwhich noRNAseq datawere obtained, were excluded from further biomarker analyses. CD8A, CD8amolecule; CD8B, CD8bmolecule; IFNG, interferon gamma;
MSI-H, microsatellite instability-high; MSS, microsatellite stable; NE, not evaluable; TGFB1, transforming growth factor beta 1; TPM, transcript-per-million; TWIST1,
twist family bHLH transcription factor 1; VIM, vimentin. aTumor neoantigen count unavailable.
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